Meeting
2024 ASCO Quality Care Symposium
Alopecia as an uncommon side effect of single postoperative instillation of gemcitabine in patients with non-muscle-invasive urothelial carcinoma of the bladder.
Authors
Anosh Dadabhoy
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Anosh Dadabhoy , Seyedeh Sanam Ladi Seyedian , Chirag Doshi , Anne K. Schuckman , Siamak Daneshmand
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Palliative and Supportive Care
Sub Track
Symptom Prevention, Assessment, and Management
Citation
JCO Oncol Pract 20, 2024 (suppl 10; abstr 274)
DOI
10.1200/OP.2024.20.10_suppl.274
Abstract #
274
Poster Bd #
E19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.
First Author: Martin Egger
Poster
2023 ASCO Annual Meeting
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
First Author: Guarionex Joel DeCastro
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer.
First Author: Christopher Gaffney
Poster
2021 Genitourinary Cancers Symposium
A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer.
First Author: Manuel R. De Jesus Escano